BACKGROUND AND OBJECTIVES: Both valganciclovir and high-dose valacyclovir are recommended for cytomegalovirus prophylaxis after renal transplantation. A head-to-head comparison of both regimens is lacking. The objective of the study was to compare valacyclovir prophylaxis with valganciclovir, which constituted the control group. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: In a randomized, open-label, single-center trial, recipients of renal transplants (recipient or donor cytomegalovirus-seropositive) were randomly allocated (1:1) to 3-month prophylaxis with valacyclovir (2 g four times daily) or valganciclovir (900 mg daily). Enrollment occurred from November of 2007 to April of 2012. The primary end points were cytomegalovirus DNAemia and biopsy-proven acute rejection at 12 months. Analysis was by intention to treat. RESULTS: In total, 119 patients were assigned to valacyclovir (n=59) or valganciclovir prophylaxis (n=60). Cytomegalovirus DNAemia developed in 24 (43%) of 59 patients in the valacyclovir group and 18 (31%) of 60 patients in the valganciclovir group (adjusted hazard ratio, 1.35; 95% confidence interval, 0.71 to 2.54; P=0.36). The incidence of cytomegalovirus disease was 2% with valacyclovir and 5% with valganciclovir prophylaxis (adjusted hazard ratio, 0.21; 95% confidence interval, 0.01 to 5.90; P=0.36). Significantly more patients with valacyclovir prophylaxis developed biopsy-proven acute rejection (18 of 59 [31%] versus 10 of 60 [17%]; adjusted hazard ratio, 2.49; 95% confidence interval, 1.09 to 5.65; P=0.03). The incidence of polyomavirus viremia was higher in the valganciclovir group (18% versus 36%; adjusted hazard ratio, 0.43; 95% confidence interval, 0.19 to 0.96; P=0.04). CONCLUSIONS: Valganciclovir shows no superior efficacy in cytomegalovirus DNAemia prevention compared with valacyclovir prophylaxis. However, the risk of biopsy-proven acute rejection is higher with valacyclovir.

Biomedical Centre Faculty of Medicine in Pilsen Charles University Prague Pilsen Czech Republic Hemato oncology and

Biomedical Centre Faculty of Medicine in Pilsen Charles University Prague Pilsen Czech Republic Pathology Charles University Medical School and Teaching Hospital Pilsen Czech Republic; and

Departments of Internal Medicine 1 Biomedical Centre Faculty of Medicine in Pilsen Charles University Prague Pilsen Czech Republic

Zobrazit více v PubMed

Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A, Transplantation Society International CMV Consensus Group : Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96: 333–360, 2013 PubMed

Reischig T, Jindra P, Svecová M, Kormunda S, Opatrný K, Jr., Treska V: The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 36: 146–151, 2006 PubMed

Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V: Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 87: 436–444, 2009 PubMed

Smith JM, Corey L, Bittner R, Finn LS, Healey PJ, Davis CL, McDonald RA: Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21: 1579–1586, 2010 PubMed PMC

Humar A, Gillingham K, Payne WD, Sutherland DE, Matas AJ: Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 70: 310–313, 2000 PubMed

Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, Nordal KP, Jenssen T: Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 47: 1550–1556, 2004 PubMed

Sagedal S, Hartmann A, Nordal KP, Osnes K, Leivestad T, Foss A, Degré M, Fauchald P, Rollag H: Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66: 329–337, 2004 PubMed

Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR: Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 46: 840–846, 2008 PubMed

Luan FL, Kommareddi M, Ojo AO: Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 11: 1936–1942, 2011 PubMed

Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, Viklicky O: Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 23: 1588–1597, 2012 PubMed PMC

Reischig T: Advances in cytomegalovirus-preventive strategies in solid organ transplantation: Defending pre-emptive therapy. Expert Rev Anti Infect Ther 10: 51–61, 2012 PubMed

Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P: The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10: 1228–1237, 2010 PubMed

Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F: Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 8: 975–983, 2008 PubMed

Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P: Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-year results of the IMPACT study. Transplantation 90: 1427–1431, 2010 PubMed

Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6: 2134–2143, 2006 PubMed

Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V: Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 8: 69–77, 2008 PubMed

Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC, International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group : Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340: 1462–1470, 1999 PubMed

Kielberger L, Bouda M, Jindra P, Reischig T: Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kidney Blood Press Res 35: 407–416, 2012 PubMed

Reischig T, Jindra P, Mares J, Cechura M, Svecová M, Hes O, Opatrný K, Jr., Treska V: Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 79: 317–324, 2005 PubMed

Humar A, Michaels M, AST ID Working Group on Infectious Disease Monitoring : American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 6: 262–274, 2006 PubMed

Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM, 3rd, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi A: Banff ’09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 10: 464–471, 2010 PubMed

Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, Boletis JN: A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin Microbiol Infect 11: 736–743, 2005 PubMed

Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, Valganciclovir Solid Organ Transplant Study Group : Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4: 611–620, 2004 PubMed

Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A: Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: A multicenter cohort study. Clin Infect Dis 56: 817–824, 2013 PubMed

Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC: Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation 90: 412–418, 2010 PubMed PMC

Kalil AC, Freifeld AG, Lyden ER, Stoner JA: Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS ONE 4: e5512, 2009 PubMed PMC

Reischig T: Cytomegalovirus-associated renal allograft rejection: New challenges for antiviral preventive strategies. Expert Rev Anti Infect Ther 8: 903–910, 2010 PubMed

Freeman RB, Jr.: The ‘indirect’ effects of cytomegalovirus infection. Am J Transplant 9: 2453–2458, 2009 PubMed

Dzabic M, Rahbar A, Yaiw KC, Naghibi M, Religa P, Fellström B, Larsson E, Söderberg-Nauclér C: Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 53: 969–976, 2011 PubMed

Reischig T, Nemcová J, Vanecek T, Jindra P, Hes O, Bouda M, Treska V: Intragraft cytomegalovirus infection: A randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Antivir Ther 15: 23–30, 2010 PubMed

Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG: Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143: 870–880, 2005 PubMed

Heagy W, Crumpacker C, Lopez PA, Finberg RW: Inhibition of immune functions by antiviral drugs. J Clin Invest 87: 1916–1924, 1991 PubMed PMC

Battiwalla M, Wu Y, Bajwa RP, Radovic M, Almyroudis NG, Segal BH, Wallace PK, Nakamura R, Padmanabhan S, Hahn T, McCarthy PL, Jr.: Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant 13: 765–770, 2007 PubMed

Reischig T, Prucha M, Sedlackova L, Lysak D, Jindra P, Bouda M, Matejovic M: Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. Antivir Ther 16: 1227–1235, 2011 PubMed

Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice : BK polyomavirus in solid organ transplantation. Am J Transplant 13[Suppl 4]: 179–188, 2013 PubMed

Schaub S, Hirsch HH, Dickenmann M, Steiger J, Mihatsch MJ, Hopfer H, Mayr M: Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 10: 2615–2623, 2010 PubMed

Binggeli S, Egli A, Schaub S, Binet I, Mayr M, Steiger J, Hirsch HH: Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 7: 1131–1139, 2007 PubMed

Bestard O, Lucia M, Crespo E, Van Liempt B, Palacio D, Melilli E, Torras J, Llaudó I, Cerezo G, Taco O, Gil-Vernet S, Grinyó JM, Cruzado JM: Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant 13: 1793–1805, 2013 PubMed

Kayler L, Zendejas I, Schain D, Magliocca J: Ureteral stent placement and BK viremia in kidney transplant recipients. Transpl Infect Dis 15: 202–207, 2013 PubMed

A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients

Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial

Zobrazit více v PubMed

ANZCTR
ACTRN1260000016033